CurrentCommunity-CarePolicy N/A

Viscosupplements (hyaluronic acid) — Medical Benefit Medication Utilization Policy

Policy governing medical benefit coverage, authorization, quantity limits, and continuation criteria for viscosupplementation (hyaluronic acid derivatives) for symptomatic knee osteoarthritis for Community-Care members.

Policy Summary

PayerCommunity-Care

PolicyViscosupplements (hyaluronic acid) — Medical Benefit Medication Utilization Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization with documentation showing specialist involvement, ≥5 ACR criteria met, ≥3 months of required prior trials, and trial/interval requirements for continuation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsauthorization period per approval

1 series / 180dquantity limit per knee

≥3 monthsrequired prior trial duration (non‑pharm)

≥3 monthsrequired prior trial duration (pharmacologic)

≥6 monthsrequired interval since prior cycle

Policy Summary

PayerCommunity-Care

PolicyViscosupplements (hyaluronic acid) — Medical Benefit Medication Utilization Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization with documentation showing specialist involvement, ≥5 ACR criteria met, ≥3 months of required prior trials, and trial/interval requirements for continuation.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Intra-articular Hyaluronan (Knee)

Initial Therapy

Covered when ALL of the following are met

Initial Approval for viscosupplementation: 1) Prescribed by or in consultation with a rheumatology, orthopedic, sports medicine, or pain medicine specialist; 2) Diagnosis of symptomatic osteoarthritis of the knee; 3) Meets >=5 of the American College of Rheumatology (ACR) clinical and laboratory criteria (bony enlargement; bony tenderness; crepitus on active motion; erythrocyte sedimentation rate <40 mm/hr; morning stiffness <30 minutes; no palpable warmth of synovium; age >50 years; rheumatoid factor <1:40 titer; synovial fluid consistent with OA [clear fluid of normal viscosity and WBC <2,000/mm3]); 4) Trial of >=3 months of non-pharmacologic therapies (education, strength training, range of motion exercises, assistive devices, weight loss) was ineffective; 5) Trial of >=3 months of acetaminophen, topical capsaicin, and topical topical NSAID were ineffective, contraindicated, or not tolerated; 6) Trial of intra-articular corticosteroid therapy was ineffective, contraindicated, or not tolerated; 7) Not scheduled to undergo a total knee replacement within 6 months of treatment>=5 ACR criteria

All listed elements must be documented

Continuation Therapy

Covered for continuation when ALL of the following are met

Continuation of Therapy: 1) Diagnosis of symptomatic osteoarthritis of the knee; 2) At least 6 months have elapsed since the prior treatment cycle; 3) Documentation of significant improvement in pain and function resulting from prior intra-articular hyaluronic acid therapy; 4) Not scheduled to undergo a total knee replacement within 6 months of treatment>=6 months since prior cycle

Clinical improvement must be documented

Planned total knee replacement within 6 months of the proposed viscosupplementation injection is an exclusion to approval; members scheduled for total knee arthroplasty within that time frame are not eligible for coverage.

When documentation does not meet the stated initial or continuation criteria, the request is considered not medically necessary. Examples include insufficient or undocumented prior trials of required non‑pharmacologic or pharmacologic therapies (each ≥ 3 months when required), failure to document fulfillment of ≥ 5 ACR clinical/laboratory criteria, inadequate interval since the prior hyaluronan treatment (less than 6 months), or presence of a planned total knee replacement within 6 months.

Relevant Codes and Limits

Applicable HCPCS CodesHCPCS

J7318	Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg.
J7320	Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg.
J7321	Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra- articular injection, per dose.
J7322	Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg.
J7323	Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose.
J7324	Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose.
J7325	Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg.
J7326	Hyaluronan or derivative, gel-one, for intra-articular injection, per dose.
J7327	Hyaluronan or derivative, monovisc, for intra-articular injection, per dose.
J7328	Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg.

1–10 of 13

1/2

Minimum interval between treatment cycles

Minimum intervalAt least 180 days between dosage series (1 dosage series per knee every 180 days)

Continuation timingContinuation therapy requires at least 6 months (≈180 days) since the prior treatment cycle

Quantity limit per kneeAuthorized quantity: up to 1 dosage series per knee every 180 days

Authorization period relationApprovals are issued for a 6-month authorization period consistent with the 180-day interval

Provider Requirements and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required per payer processes for intra-articular hyaluronan (viscosupplementation). A prior authorization request must identify the specific HCPCS code(s) for the product to be administered.

Affected HCPCS codes: J7318, J7320, J7321, J7322, J7323, J7324, J7325, J7326, J7327, J7328, J7329, J7331, J7332
Authorization frequency limit: up to 1 dosage series per knee every 180 days
Authorization period: up to 6 months if approved

Documentation Required

Required Documentation to Support Approval

Provide complete documentation to support medical necessity and to avoid denial. Documentation must demonstrate specialist involvement, the diagnosis and severity of symptomatic knee osteoarthritis, fulfillment of ACR criteria, prior conservative therapy trials, and results of prior intra-articular corticosteroid therapy.

Prescribed by or in consultation with a rheumatology, orthopedic, sports medicine, or pain medicine specialist
Diagnosis: symptomatic osteoarthritis of the knee
ACR criteria: documentation that the patient meets ≥5 of the following clinical/laboratory features — bony enlargement; bony tenderness; crepitus on active motion; erythrocyte sedimentation rate <40 mm/hr; <30 minutes of morning stiffness; no palpable warmth of synovium; age >50 years; rheumatoid factor <1:40 titer; synovial fluid clear with normal viscosity and WBC <2,000/mm3
Prior non-pharmacologic therapy: trial ≥3 months (education, strength training, ROM exercises, assistive devices, weight loss) that was ineffective
Prior pharmacologic therapy: trial ≥3 months of acetaminophen, topical capsaicin, and topical NSAID that were ineffective, contraindicated, or not tolerated
Trial of intra-articular corticosteroid therapy documented as ineffective, contraindicated, or not tolerated
Not scheduled for total knee replacement within 6 months of requested treatment
For continuation requests: documentation of symptomatic knee osteoarthritis, ≥6 months since prior hyaluronic acid treatment, and significant improvement in pain and function from prior hyaluronic acid therapy

Denial Risk

Denial Triggers

Incomplete or missing documentation of any of the required elements above is a denial trigger. Common denial reasons include lack of specialist prescription/consultation, failure to document ≥5 ACR criteria, absence of documented trials of required non‑pharmacologic or pharmacologic therapies, no documentation regarding corticosteroid trial, or evidence the patient is scheduled for knee replacement within 6 months.

Denial triggers: missing specialist involvement, insufficient ACR criteria (fewer than 5 documented), no documented ≥3 month trials of non‑pharmacologic therapies, no documented ≥3 month trials of required pharmacologic agents, no documentation of corticosteroid trial, scheduled TKR within 6 months

Background

Viscosupplementation delivers intra‑articular hyaluronic acid derivatives (e.g., Durolane, Euflexxa, Gel‑One, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Synvisc, and others) intended to treat symptomatic osteoarthritis of the knee after failure of conservative measures. The policy requires specialist involvement, documentation that the patient meets at least 5 ACR clinical/laboratory criteria, and evidence of unsuccessful or contraindicated/intolerant trials of specified non‑pharmacologic and pharmacologic therapies (including intra‑articular corticosteroid trial status) before viscosupplementation is approved.

OpenPayer

Viscosupplements (hyaluronic acid) — Medical Benefit Medication Utilization Policy

Coverage Criteria for Intra-articular Hyaluronan (Knee)

Relevant Codes and Limits

Provider Requirements and Authorization

Background

Definitions and Clinical Criteria